-
European Radiology: Radiomics makes the identification of multiple myeloma and metastases no longer a headache!
Time of Update: 2022-02-18
Recently, a study published in the journal European Radiology used the most common imaging features to establish a vertebral MRI-based radiomic model for the identification of MM and metastases , and compared and analyzed the performance of the model with different EPV values.
-
European Radiology: This CT feature predicts the prognosis of PDAC patients
Time of Update: 2022-02-18
Two radiologists evaluated CT diagnoses that were negative ((i) tumors surrounded by pancreatic parenchyma and (ii) tumors touching the surface of the pancreas) or positive ((iii) had a peripancreatic nodular appearance and/or invasive growth tumor) with extrapancreatic progression .
-
Clinical Lung Cancer: Delayed dosing of immune checkpoint inhibitors (ICIs) under the influence of the new crown epidemic does not affect the efficacy of NSCLC patients
Time of Update: 2022-02-18
. Recently, Clinical Lung Cancer published a retrospective study to evaluate the safety and efficacy of delayed administration (EI) of immune checkpoint inhibitor (ICI) in patients with non-small cell lung cancer under the influence of the new coronary pneumonia epidemic.
-
This kind of high blood pressure is curable!
Time of Update: 2022-02-16
It is mainly due to adrenal gland lesions (such as hyperplasia, nodules, tumors) that lead to abnormal secretion of adrenal hormones, which ultimately induces increased blood pressure in patients .
-
Science sub-issue cover: Zhang Xu et al. of Jiangsu University develop engineered exosomes to treat cancer
Time of Update: 2022-01-25
This study developed a simple and efficient engineered neutrophil-derived exosome (N-Ex) and neutrophil-derived nanovesicle (NNV) as a safe and effective drug for tumor therapy delivery vehicle .
In addition, the research team also modified neutrophil-derived exosomes (N-Ex) with superparamagnetic iron oxide nanoparticles (SPIONs) to achieve higher tumor-targeted therapeutic effects .
-
Forget medicine into medical insurance!
Time of Update: 2022-01-25
The year 2021 is a year of rapid progress in clinical research and clinical practice of China's original third-generation EGFR-TKI (Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor) drugs for the treatment of advanced non-small cell lung cancer (NSCLC) .
-
In-hospital management of patients with thrombocytopenia due to hematological diseases (6) - Thrombocytopenia due to lymphoma chemotherapy
Time of Update: 2022-01-25
The evaluation and procedures of lymphoma CIT are similar to those of leukemia CIT (see In-hospital management of patients with thrombocytopenia due to hematological diseases (5)—thrombocytopenia due to chemotherapy in acute leukemia), but it should be noted that different chemotherapy regimens may cause The incidence of lymphoma CIT is different, such as ICE, AI (doxorubicin, ifosfamide), MAID (doxorubicin, ifosfamide, dacarbazine).
-
O drug + chemotherapy significantly improves PFS in patients with such upper gastrointestinal tumors. The first update of "The Lancet" after Christmas is here!
Time of Update: 2022-01-25
On January 11, a study investigating the efficacy of nivolumab + chemotherapy (oxaliplatin-based) versus placebo + chemotherapy in first-line treatment of patients with HER2-negative, unresectable advanced or recurrent gastric or gastroesophageal junction cancer Published in Lancet Oncol .
-
Annual Inventory Professor Huang Wenrong: In the era of new drugs, autologous hematopoietic stem cell transplantation is still unshakable in the treatment of multiple myeloma
Time of Update: 2022-01-25
In recent years, the continuous progress of therapeutic drugs such as proteasome inhibitors, immunomodulators, and monoclonal antibodies has led to a significant improvement in the survival rate of MM patients .
-
6 sheets to master the 2022 v2 gastric cancer treatment plan to understand the NCCN guidelines in 1 minute
Time of Update: 2022-01-25
Recently, the National Comprehensive Cancer Network (NCCN) updated the 2022 v2 guidelines for the diagnosis and treatment of gastric cancer .
-
The original Chinese medicine icariin soft capsule was approved for marketing, filling the precision treatment plan for advanced hepatocellular carcinoma
Time of Update: 2022-01-25
"Icaritin (Acoradine) Soft Capsules, as a small molecule immunomodulatory drug, can significantly prolong the overall survival and improve the quality of life of the advanced hepatocellular carcinoma-enriched population with heavier baseline and poor prognosis, and Has significant clinical safety advantages.
-
Immunotherapy not working?
Time of Update: 2022-01-25
Through the analysis of different tumor samples, including gene sequencing, cell imaging and surface marker classification, as well as clinical data analysis, the study divided the tumors into 12 groups based on the characteristics of the tumor microenvironment, which they called tumor prototypes .
-
Safety analysis of dual PI3Kδ/CK1ε inhibitor Umbralisib in patients with relapsed/refractory lymphoma
Time of Update: 2022-01-25
The 4 studies include: The TGR-1202-101 study (NCT01767766) is a Phase I dose escalation trial evaluating umbralisib in R/R, histologically confirmed hematological malignancies (B-cell NHL, CLL, peripheral T-cell lymphoid safety and efficacy in patients with cancer and HL) .
-
[Wednesday Reading] Professor Liu Qifa: Based on AML, looking forward to the future, comprehensively analyzing the impact of IDH mutation on the development and treatment of AML
Time of Update: 2022-01-25
Combination of demethylating agents in newly diagnosed AML: a phase I/II trial in newly diagnosed IDH1-mutant AML patients showed that ivonib combined with azacitidine induced leukemia cell differentiation and apoptosis with an ORR of 78.
-
JCO: Capecitabine + chemotherapy can prolong the survival of patients with early breast cancer; this traditional Chinese medicine is approved for first-line treatment of liver cancer indications... Tumor Information
Time of Update: 2022-01-25
(If you want the original text of the document, you can add Xiaobian WeChat yxj_oncology to get it) Key points: Lancet Oncol: O drug + cabozantinib combination therapy can improve progression-free survival and improve patient-reported outcomes JCO: Add capecitabine on the basis of adjuvant chemotherapy A new drug that can prolong the survival of patients with early breast cancer: traditional Chinese medicine for liver cancer!
-
2021 CSCO Differentiated Thyroid Cancer Diagnosis and Treatment Guidelines Series Interpretation - Prof. Luo Yukun's Interpretation of Ablation Therapy
Time of Update: 2022-01-25
A long-term follow-up study from South Korea showed that ultrasound-guided radiofrequency ablation has good efficacy in low-risk PTMC patients, and no local tumor progression, distant metastasis, or surgery-related death occurred during more than 5 years of follow-up.
-
Express uses red blood cells to extensively stimulate the immune system, and innovative anti-cancer therapy enters the clinic
Time of Update: 2022-01-24
▎WuXi AppTec Content Team Editor On January 13, 2022, Rubius Therapeutics announced that its Phase 1/2 clinical trial of RTX-224, a red blood cell therapy designed to broadly stimulate the immune system, has completed the first patient dosing for For the treatment of certain patients with relapsed/refractory or locally advanced solid tumors, including non-small cell lung cancer, cutaneous melanoma, head and neck squamous cell carcinoma, urothelial (bladder) cancer, and triple-negative breast cancer .
-
The results of the two major "D+T" studies have both been released, some people are happy and some are worried about tumor information
Time of Update: 2022-01-24
*Only for medical professionals to read and reference for 1 minute a day, to give you professional "talks" in the tumor circle! (If you need the original text, you can add the editor's WeChat yxj_onc
-
Prof. Gang Guo: Clinical value and timing of cytoreductive nephrectomy for metastatic renal cancer
Time of Update: 2022-01-24
Application and role of CN in the era of targeted combination therapy Checkmate9ER study: results of subgroup analysis stratified by prior nephrectomy Checkmate9ER study aims to evaluate nivolumab + cabozantinib vs sunitinib in advanced stage Efficacy in kidney cancer .
-
Lung cancer 3-year survival rate increased by 10%, cancer mortality decreased by 32%: what do we learn from CA report?
Time of Update: 2022-01-24
In the past ten years, why has the 3-year survival rate of lung cancer in the United States increased by 10%?
With the reduction of smoking population, early diagnosis and improvement of treatment options, the cancer mortality rate has been decreasing year by year .
